Clinical trials: Infliximab, completed
Spondylarthropathies
Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies
Tumor necrosis factor (TNF) alpha is a pro-inflammatory cytokine playing a significant role in the pathogenesis of the spondyloarthropathies (SpA).
- Trial name
- NCT00591201
- Testing
- infliximab
- Where
- Mexico
- Volunteers
- 26 people
- Sponsor
- Hospital General de Mexico
Crohn's Disease
The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy
This is a pilot study to estimate the efficacy of infliximab in inducing and maintaining healing of lesions in the mucosa of subjects with Crohn's disease involving their small bowel.
- Trial name
- ICE (NCT01181765)
- Testing
- Infliximab 5 mg/kg body weight infused over 2 hours
- Where
- 2 sites in Canada
- Volunteers
- 1 people
- Sponsor
- Janssen Inc.
Rheumatoid Arthritis, Spondyloarthritis
The NOR-SWITCH Study
The purpose of this study is to assess the safety and efficacy of switching from Remicade to the biosimilar treatment Remsima in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis, Ulcerative Colitis
- Trial name
- NOR-SWITCH (NCT02148640)
- Testing
- Innovator infliximab, Biosimilar infliximab
- Where
- 30 sites in Norway
- Volunteers
- 482 people
- Sponsor
- Diakonhjemmet Hospital
Psoriasis
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18.
- Trial name
- TIPS (NCT00686686)
- Testing
- Infliximab
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Reperfusion Injury
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
The purpose of this study is to establish the effectiveness of the combined drug approach (anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta, C1-inhibitor, glutathione, alfa-tocopherol…
- Trial name
- CAPITL (NCT02251041)
- Testing
- Antithrombin-III, Infliximab, Apotransferrin
- Where
- Belgium
- Volunteers
- 143 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Ulcerative Colitis
Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)
Ulcerative colitis (UC) is a chronic, progressive immunologically mediated disease affecting nearly 1 million Americans. Up to one third of patients with UC will require hospitalization for severe disease (termed 'acute severe…
- Trial name
- MASCC (NCT03669822)
- Testing
- Standard of care
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Johns Hopkins University
Ankylosing Spondylitis
Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis
ASART-1 clinical study is a phase 1 study which carried out to establish the pharmacokinetic equivalence and equal safety profile of BCD-055 (infliximab manufactured by JSC BIOCAD, Russia) and Remicade when used as multiple IV…
- Trial name
- NCT02359903
- Testing
- Infliximab (BCD-055), Infliximab (Remicade)
- Where
- 6 sites in Belarus, Russia
- Volunteers
- 90 people
- Sponsor
- Biocad
Plaque Psoriasis, Psoriatic Arthritis
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment…
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized), Psoriatic Erythroderma
- Trial name
- NCT01680159
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Tanabe Pharma Corporation
Rheumatoid Diseases, Rheumatoid Arthritis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
To assess persistence of CT-P13 in patients with Rheumatoid Diseases (Rheumatoid arthritis [RA], ankylosing spondylitis [AS], and psoriatic arthritis [PsA]) who are naïve to biologics or are switching from stable Remicade to…
- Conditions
- Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- PERSIST (NCT02605642)
- Testing
- CT-P13
- Where
- 38 sites in Bulgaria, Canada and 5 more
- Volunteers
- 351 people
- Sponsor
- Pfizer
Graft-Versus-Host Disease
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
This study will evaluate the efficacy of infliximab in reducing the incidence of grade II-IV acute graft versus host disease by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell transplant.
- Trial name
- NCT00201799
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hidradenitis Suppurativa
Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa
The aim of this clinical trial is to assess the efficacy and safety of Infliximab-dyyb biosimilar in patients of resistant Hidradenitis suppurativa.
- Trial name
- NCT05663268
- Testing
- Infliximab-dyyb biosimilar
- Where
- Pakistan
- Volunteers
- 37 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Rheumatoid Arthritis, Spondyloarthritis
Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease
TNFα inhibitors have revolutionized the management of patients suffering from inflammatory diseases in the field of rheumatology.
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis
- Trial name
- SIC2 (NCT05424926)
- Testing
- collection of clinical parameters and blood sample
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers
Comparing the structural effects of TNFi and tocilizumab on the periarticular bone by performing a comprehensive analysis of the periarticular bone changes in RA patients treated with either TNFi or tocilizumab in a longitudinal…
- Trial name
- Re-Bone (NCT02778789)
- Testing
- Tocilizumab, TNF-alpha Inhibitor
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
The purpose of this study was to demonstrate similarity of NI-071 (proposed biosimilar to infliximab) to US REMICADE® (reference product) in terms of safety and efficacy in participants with rheumatoid arthritis (RA) not…
- Trial name
- NCT02990806
- Testing
- NI-071, Remicade
- Where
- 134 sites in United States, Czechia and 6 more
- Volunteers
- 683 people
- Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
Crohn's Disease
Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy
This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's disease during anti TNF-α (infliximab)…
- Trial name
- NCT01661257
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Crohn's Disease, Ulcerative Colitis
Endomicroscopy in IBD Patients
The aim of the study is to analyze the mechanism of action of infliximab at the endomicroscopic level and to analyze mucosal healing - i.e.
- Trial name
- EARLY (NCT01417728)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Inflammatory Bowel Diseases, Crohn Disease
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
Prospective, multicentre trial which the biologic treatment will be initiated by clinical indication. The treatment selection anti-TNFα (infliximab, adalimumab or golimumab), vedolizumab, ustekinumab and tofacitinib will be made…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- BioIBD (NCT03885713)
- Testing
- Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
- Where
- 21 sites in Spain
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Arthritis, Rheumatoid, Spondylitis, Ankylosing
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
A study to describe the one-year persistence in participants treated by Flixabi (infliximab) or Imraldi (Adalimumab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Crohn's Disease
- Trial name
- PERFUSE (NCT03662919)
- Testing
- Infliximab, Adalimumab
- Where
- 60 sites in France
- Volunteers
- 2,274 people
- Sponsor
- Biogen
Psoriasis
Regulatory T-cells in Psoriasis Patients as Targets for Therapy
The aim of this study is to understand which therapies will suppress effector cells and promote regulatory T cells and To test whether patients with a better response to therapy and longer psoriasis-free periods develop a higher…
- Trial name
- NCT01233583
- Testing
- Dovobet, neotigason, etanercept, adalimumab. infliximab
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen